Learning points
In a full economic evaluation, costs and consequences are often incorporated into decision models to compare interventions.
An economic evaluation is only useful to a healthcare provider if the model assumptions and estimates are accurate With limited resources, there is a growing impetus to make cost-conscious medical decisions. The 'valuation' of interventions can take different forms in economic evaluation, each one with its own methodology and interpretation. Making a trustworthy 'valuation' requires comparative analysis of healthcare strategies in terms of their costs (e.g. time, equipment, medication -assigned a monetary value) and consequences (e.g. change in health state, life-years gained). The most affordable option is not always the most effective.
To perform an economic evaluation, costs and consequences can be incorporated into a model -e.g. decision tree, Markov model (Pedersen et al., BJOG 2017; 124: 474-84) or a clinical trial (Walker et al., BJOG 2017; 124:929-34) . The types of costs and consequences included depend on the perspective that is used. Often a societal perspective is used for health policy questions and is distinct from the narrower hospital (payer) or individual (patient) perspectives.
Health economic analyses report the 'valuation' in terms of its cost per unit of consequence. To compare strategies, often an incremental cost-effectiveness ratio (ICER) is calculated; the ICER is the difference in costs between strategies, divided by the difference in outcomes. However, this does not allow comparison of the interventions for different conditions, making it hard to decide how best to spend available funds. This concept is crucial at a national level when deciding what the Government should spend its money on (e.g. expensive chemotherapy that could benefit a small number of people or inexpensive screening for Group B Streptococcus in mothers). These comparisons are made possible by using quality-adjusted life-years (QALYs), derived by estimating the years of life remaining for an individual undergoing an intervention and weighting each year with a quality-of-life score ranging from 0 (death) to 1 (perfect health). One QALY is equivalent to living a whole year in full health.
An often misunderstood concept in economic evaluation is that the most affordable health intervention is better but this may not be so when all consequences are considered (e.g. the costs of further treatments required when a cheap strategy has a high failure rate or longer hospital stay). Thresholds are used to help decide what constitutes value for money. In the UK, the National Institute for Health and Care
Excellence uses a 'willingness to pay threshold' of £30,000 per QALY, meaning that if an intervention is additionally effective in increasing QALYs by one or more at a cost below this threshold then it is a viable preferred strategy.
Economic evaluation can appear complicated but understanding the fundamentals is the key. For example, no amount of analytical complexity can hide the basic truth that if an intervention is not effective, it cannot be cost-effective.
Useful resources
The CHEERS statement provides reporting standards for health economic evaluations (Husereau et al., BJOG 2013; 120:765-70 
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